Source:http://linkedlifedata.com/resource/pubmed/id/19190977
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2009-4-3
|
pubmed:abstractText |
Deep mycosis (aspergillus pneumonia (AsP)) and carinii pneumonitis (PCP) are complications of immunosuppressive treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The objective was to clarify the clinical significance of plasma titer of antibody against beta-glucans (anti-BG antibody) as a predictor of complications such as AsP or PCP and the prognosis of patients. Enzyme-linked immunosorbent assay was used to measure the plasma titer of antibodies against beta-glucans (BG) from Candida albicans in 22 healthy subjects and 52 patients with various stages of AAV. The mean plasma titer of the anti-BG antibody was 2,677 +/- 1,686 U in healthy subjects, 691 +/- 522 U in patients with untreated active vasculitis (n = 14), and 547 +/- 416 U in patients soon after immunosuppressive treatment (n = 24). Healthy subjects had significantly higher antibody titers than the other two groups (P < 0.05). Repeated measurements over the clinical course of AAV revealed an increase during remission to 1,180 +/- 130 U (n = 11), while there was a significant rapid decrease to 369 +/- 441 U (P < 0.01) concomitantly with elevation in plasma C-reactive protein and BG levels in patients with AAV that had AsP or PCP infection. Antifungal therapy resulted in a rapid rise of anti-BG antibody titer. Experiments in mice suggested that the anti-BG antibody neutralizes BG. Rapid decrease of the anti-BG antibody titer may be a useful indicator for diagnosis of the presence of AsP or PCP and for estimating the prognosis of patients with these opportunistic infections during immunosuppressive treatment of AAV.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1434-9949
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
565-71
|
pubmed:meshHeading |
pubmed-meshheading:19190977-Aged, 80 and over,
pubmed-meshheading:19190977-Antibodies, Antineutrophil Cytoplasmic,
pubmed-meshheading:19190977-Antifungal Agents,
pubmed-meshheading:19190977-Aspergillus,
pubmed-meshheading:19190977-Candida albicans,
pubmed-meshheading:19190977-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:19190977-Female,
pubmed-meshheading:19190977-Humans,
pubmed-meshheading:19190977-Immunosuppressive Agents,
pubmed-meshheading:19190977-Male,
pubmed-meshheading:19190977-Middle Aged,
pubmed-meshheading:19190977-Mycoses,
pubmed-meshheading:19190977-Pneumonia,
pubmed-meshheading:19190977-Remission Induction,
pubmed-meshheading:19190977-Reproducibility of Results,
pubmed-meshheading:19190977-Vasculitis,
pubmed-meshheading:19190977-beta-Glucans
|
pubmed:year |
2009
|
pubmed:articleTitle |
Rapid decrease of anti-beta-glucan antibody as an indicator for early diagnosis of carinii pneumonitis and deep mycotic infections following immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
|
pubmed:affiliation |
Renal Unit of the Department of Internal Medicine, Hachioji Medical Center of Tokyo Medical University, Hachioji, Tokyo, Japan. myoshida@tokyo-med.ac.jp
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|